<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04107220</url>
  </required_header>
  <id_info>
    <org_study_id>CAN0014</org_study_id>
    <nct_id>NCT04107220</nct_id>
  </id_info>
  <brief_title>Comparison of BNP and NT-proBNP in the Management of Patients With Chronic and Acute Heart Failure</brief_title>
  <official_title>Comparison of BNP and NT-proBNP in the Management of Patients With Chronic and Acute Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alere, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Michael's Hospital, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the changes in B-type Natriuretic Peptide (BNP) and
      amino-terminal fragment of proBNP (NT-proBNP) in outpatients managed in the heart failure
      (HF) clinic initiated on the Angiotensin Receptor Neprilysin Inhibitor (Entresto) and
      directly compare the prognostic values of BNP and NT-proBNP in patients admitted with acute
      decompensated HF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Both natriuretic peptides (NP), namely B-type NP (BNP) and amino-terminal fragment of proBNP
      (NT-proBNP), have an established role in the management of patients with heart failure
      (HF).[1] However, the clinical utility of BNP has recently been questioned with the
      PARADIGM-HF trial, which demonstrated increased BNP and reduced NT-proBNP levels following
      the administration of Entresto, a newly approved angiotensin receptor neprilysin inhibitor
      (ARNI).[2.3] The increase in BNP was thought to be reflective of reduced metabolism of BNP as
      a result of neprilysin inhibition.[2] However, this claim was based on observations of three
      points in time and with wide confidence intervals.[3] In addition, there has been no attempt
      to demonstrate dose relationships. Furthermore, although both BNP and NT-proBNP have each
      been shown to predict HF readmission in hospitalized patients [1,4,5] the relative utility
      between the two NPs for this prediction remains unclear. We therefore hypothesize that once
      beyond the initiation of ARNI therapy, BNP and NT-proBNP will be equally predictive of
      clinical events in patients with HF.

      The studies comprise of two separate protocols:

      A. Outpatient Protocol - the effect of Entresto measuring the changes in the NT-proBNP and
      BNP test results. This protocol will be conducted on ambulatory outpatients initiating on
      Entresto. Patients will have blood sampling for the measurements of BNP and NT-proBNP at
      baseline, at the first and second up titration in dose of Entresto, and at 6 months and 1st
      year after starting Entresto.

      B. Inpatient Protocol-predicting outcomes. This will be conducted on patients admitted for
      acute decompensated HF. Blood sampling for BNP and NT-proBNP will be collected in different
      time points (admission, hospital discharge, 30th day, 90th day, and 180th day) and measure
      its changes.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Out Patient Protocol</measure>
    <time_frame>Baseline, 2 weeks, 4 weeks, 6 months, and 12 months</time_frame>
    <description>Measuring the changes with NT-prooBNP and BNP.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>In Patient Protocol</measure>
    <time_frame>Admission, discharge, 30th day post-discharge, 60th day post-discharge, and 180 days post discharge</time_frame>
    <description>Measuring the changes with NT-prooBNP and BNP.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>one arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>One arm study patients where NT-proBNP and BNP tests will be monitored.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sacubitril/Valsartan</intervention_name>
    <description>Effect of Sacubitril/Valsartan on BNP and NT-proBNP</description>
    <arm_group_label>one arm</arm_group_label>
    <other_name>Entresto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Out Patient Protocol - Patients with chronic heart failure being followed in the heart
        failure clinic eligible to switch angiotensin converting enzyme inhibitors (ACEI) or
        angiotensin receptor blockers (ARB) to ARNI (Entresto).

        In Patient Protocol - Patients admitted due to acute decompensated heart failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gordon W Moe, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Moe GW, Ezekowitz JA, O'Meara E, Lepage S, Howlett JG, Fremes S, Al-Hesayen A, Heckman GA, Abrams H, Ducharme A, Estrella-Holder E, Grzeslo A, Harkness K, Koshman SL, McDonald M, McKelvie R, Rajda M, Rao V, Swiggum E, Virani S, Zieroth S, Arnold JM, Ashton T, D'Astous M, Chan M, De S, Dorian P, Giannetti N, Haddad H, Isaac DL, Kouz S, Leblanc MH, Liu P, Ross HJ, Sussex B, White M; Canadian Cardiovascular Society. The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: anemia, biomarkers, and recent therapeutic trial implications. Can J Cardiol. 2015 Jan;31(1):3-16. doi: 10.1016/j.cjca.2014.10.022. Epub 2014 Dec 19. Erratum in: Can J Cardiol. 2016 Mar;32(3):394.</citation>
    <PMID>25532421</PMID>
  </reference>
  <reference>
    <citation>McMurray JJ, Packer M, Solomon SD. Neprilysin inhibition for heart failure. N Engl J Med. 2014 Dec 11;371(24):2336-7. doi: 10.1056/NEJMc1412654.</citation>
    <PMID>25494275</PMID>
  </reference>
  <reference>
    <citation>Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, Bělohlávek J, Böhm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, Gonzàlez-Medina A, Hagège AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, Kozan Ö, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC; PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015 Jan 6;131(1):54-61. doi: 10.1161/CIRCULATIONAHA.114.013748. Epub 2014 Nov 17.</citation>
    <PMID>25403646</PMID>
  </reference>
  <reference>
    <citation>Logeart D, Thabut G, Jourdain P, Chavelas C, Beyne P, Beauvais F, Bouvier E, Solal AC. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol. 2004 Feb 18;43(4):635-41.</citation>
    <PMID>14975475</PMID>
  </reference>
  <reference>
    <citation>Maisel A, Mueller C, Adams K Jr, Anker SD, Aspromonte N, Cleland JG, Cohen-Solal A, Dahlstrom U, DeMaria A, Di Somma S, Filippatos GS, Fonarow GC, Jourdain P, Komajda M, Liu PP, McDonagh T, McDonald K, Mebazaa A, Nieminen MS, Peacock WF, Tubaro M, Valle R, Vanderhyden M, Yancy CW, Zannad F, Braunwald E. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008 Sep;10(9):824-39. doi: 10.1016/j.ejheart.2008.07.014. Epub 2008 Aug 29. Review.</citation>
    <PMID>18760965</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 30, 2016</study_first_submitted>
  <study_first_submitted_qc>September 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2019</study_first_posted>
  <last_update_submitted>September 25, 2019</last_update_submitted>
  <last_update_submitted_qc>September 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BNP</keyword>
  <keyword>NT-proBNP</keyword>
  <keyword>ARNI</keyword>
  <keyword>Sacubitril/Valsartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

